We're preparing something groundbreaking. The ALS Research Archive will be available shortly.
Launching Q2 2025
Investigating the treatment landscape for Amyotrophic Lateral Sclerosis — from FDA trial failures and supplements to virus-induced neuroinflammation, GcMAF, vitamin D, and novel natural therapeutic strategies.
Over 40 promising ALS treatments spanning 1995–2025 failed to receive FDA approval despite initial promise. This analysis examines every major therapeutic category — anti-glutamatergic, anti-inflammatory, neuroprotective, neurotrophic, antisense oligonucleotides, and more — revealing a consistent pattern of failure and a clinical trial success rate below 5%.
A practical guide covering supplements with preliminary evidence, alternative treatments beyond clinical trials, respiratory support strategies, riluzole interactions, and prioritized recommendations — from antioxidants and amino acids to non-invasive ventilation and breathing exercises.
Examining the evidence for viral involvement in ALS — from endogenous retrovirus HERV-K activation regulated by TDP-43 to exogenous retroviruses, enteroviruses, and herpesviruses. Covers microglial activation, astrocyte-mediated inflammation, T-cell infiltration, cytokine cascades, and therapeutic interventions targeting neuroinflammatory pathways.
A systematic review of 300 research papers examining GcMAF (Gc protein-derived Macrophage Activating Factor) and its potential role in ALS. Covers VDBP system alterations in ALS patients, CLEC10A receptor interactions, macrophage activation mechanisms, and the current evidence gap between biological plausibility and clinical proof.
Twelve novel therapeutic strategies addressing ALS research gaps — from enhanced bioavailability formulations (curcumin-piperine, intranasal resveratrol) and multi-pathway combinations to microbiome-targeted interventions, epigenetic modulation, nanoparticle delivery systems, and autophagy-mitophagy enhancement complexes.
A systematic review of 2,556 research papers examining vitamin D and ALS — covering the 82% deficiency prevalence among patients, CYP27B1 upregulation as a novel biomarker, anti-inflammatory and neuroprotective mechanisms, clinical trial evidence, and personalized supplementation protocols.
A multi-modal analysis identifying novel treatments across pharmaceutical, gene-based, herbal/natural, and technological interventions — cross-referencing ALS mechanisms with Alzheimer's, Parkinson's, and MS to surface repurposed drugs and combination therapies.
The molecular underpinnings of ALS — from SOD1, TDP-43, and C9orf72 mutations to interconnected cycles of protein misfolding, mitochondrial dysfunction, glutamate excitotoxicity, oxidative stress, and neuroinflammation driving motor neuron death.
Promising drug candidates including ABBV-CLS-7262 for TDP-43 aggregation, AP-101 monoclonal antibody for SOD1, CNMAu-8 gold nanocrystals, and repurposed agents like metformin, tamoxifen, and deferiprone targeting multiple pathological axes.
From antisense oligonucleotides like Tofersen to CRISPR-Cas9 editing and AAV-mediated gene delivery — gene therapy approaches targeting both familial mutations and common sporadic pathological mechanisms.
Plant-derived compounds with demonstrated neuroprotective effects — madecassoside, EGCG, curcumin, resveratrol, and traditional herbal formulations acting through antioxidant, anti-inflammatory, and anti-excitotoxic pathways.
Mapping shared mechanisms between ALS, Alzheimer's, Parkinson's, Huntington's, and MS — and identifying repurposed treatments including masitinib, tamoxifen, retigabine, and antiretroviral combinations.
Brain-computer interfaces, non-invasive brain stimulation (rTMS, tDCS), and assistive technologies — advancing both symptom management and potential disease modification through P300-based BCIs and adaptive devices.
A comprehensive examination of emerging therapeutic strategies across pharmaceutical, gene-based, herbal, and technological modalities with in-depth analysis of mechanisms, cross-disease comparisons, and integrative approaches for ALS treatment.
An evidence-based clinical guide covering supplements with preliminary evidence, alternative treatments, respiratory support strategies, riluzole interactions, and practical recommendations prioritized by effectiveness level.
A comprehensive overview of the molecular targets and pathological mechanisms underlying ALS, including protein misfolding, mitochondrial dysfunction, excitotoxicity, oxidative stress, neuroinflammation, and the interconnected nature of these processes in motor neuron degeneration.